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Nevertheless, substantial unexplained variability remains in 
the development of late xerostomia. To understand this 
variation becomes increasingly important with the advent of 
more conformal radiation techniques. Our hypothesis is that 
the patient-specific late response to radiotherapy (RT) is 
associated with changes in CT images and xerostomia scores 
early after RT. 
 
Material and Methods: Parotid gland (PG) image 
characteristics were extracted from CTs before (T0) and 
after RT (6 weeks post RT) of 110 HNC patients. The 
differences between those two time points resulted in 
potential Δ CT Image Biomarkers (IBMs). These potential Δ CT 
IBMs represent geometric (20) and CT intensity (24) changes 
of the PG. Furthermore, the scored xerostomia of the 
patients before (XERbaseline) and 6 weeks post RT 
(XER6w_post), tumour, patient and dose characteristics were 
included. To identify variables that were associated with the 
endpoint moderate-to-severe xerostomia 12 months after RT 
(XER12m) whilst reducing multicollinearity, variables were 
first omitted based on inter-variables correlation. Second, 
multivariable selection was conducted by bootstrapped 
forward selection based on log-likelihood performance. The 
performance of the resulting logistic regression models was 
evaluated with the area under the ROC-curve (AUC) and 
Nagelkerke R2 index. All models were internally cross 
validated. 
 
Results: Multivariable analysis was performed with 23 Δ CT 
IBMs. The primarily selected IBM was ∆ volume (between T0 
and 6 weeks post RT) of the PG (figure) (p<0.001). Larger 
volume change was related to a higher chance of XER12m. 
Furthermore, the XER6w_post and XERbaseline were very 
prognostic. The performance of the multivariable model was 
high with an AUC of 0.89 and R2 of 0.54 (table). This model 
showed to be stable when it was internally validated (AUC-
cross=0.88, R2-cross=0.53). Moreover, dose parameters did 
not add to the performance of the model (AUC-cross=0.88, 
R2-cross=0.52). ∆ Volume made dose parameters redundant, 
suggesting that PG volume changes are related to the 
patient-specific response to dose. 
 
 
Conclusion: Change of PG volume 6 weeks post RT showed to 
be strongly related to late xerostomia. Moreover, together 
with xerostomia scores before and 6 weeks after RT, 
outstanding performance was obtained to predict XER12m. 
We believe that this model can contribute to the 
understanding of the patient-specific response to RT in 
developing late xerostomia. Secondly, it can serve as a 
quantitative measure for late damage to the PG early after 
treatment. The next step will be to investigate whether ∆ PG 
Volume and xerostomia determined early in treatment can be 
used to predict late xerostomia, to select patients with a 
large risk on late xerostomia for proton treatment. 
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Purpose or Objective: Pulmonary complications remain a 
major dose limiting factor for lung cancer radiotherapy. 
Pulmonary function loss is known to correlate with physical 
lung dose, but better prediction accuracy is desired. This 
work investigates the potential of 4D CT-based functional 
imaging to improve the prediction of radiation-induced 
pulmonary function loss. 
 
Material and Methods: 80 lung cancer patients each received 
a treatment planning 4D CT scan prior to radiotherapy. To 
quantify pulmonary functional loss the patients also 
underwent spirometry measurements of forced expiratory 
volume (FEV1) and forced vital capacity (FVC) immediately 
before radiotherapy and at 3, 6, and 9 months follow-up. For 
each patient, the pre-treatment regional ventilation was 
evaluated by performing deformable image registration (DIR) 
between the CT inhale and exhale phase images. The 
Jacobian determinant (J-1) of the DIR motion field was used 
as a ventilation surrogate. The functional mean lung dose 
(fMLD) was then defined as the regional lung dose weighted 
spatially by the regional ventilation. The physical mean lung 
dose (MLD) was calculated without ventilation 
weighting.Logistic regression was used to compare the ability 
of fMLD and MLD to predict clinical pulmonary function loss, 
defined as a reduction of the FEV1 and FVC to less than 90% 
of their initial values at 6-months post treatment. To 
minimise noise in the spirometry data, the FEV1 and FVC 
values at 6 months were estimated based on a fit to the 
available data up to 9 months post-treatment. 
 
Results: Both functional and physical lung dose correlated 
with the onset of clinical pulmonary function loss. The figure 
and table show the logistic regression results and model 
parameters respectively. We observed a 0.7 Gy decrease in 
the tolerance dose (D50) when using fMLD as opposed to MLD. 
However, the difference in log-likelihood between the MLD 
and fMLD based models was not statistically significant 
different from zero. Thus we did not observe a significant 
ESTRO 35 2016                                                                                                                                                    S229 
______________________________________________________________________________________________________ 
improvement in the prediction of pulmonary function loss 
using fMLD as opposed to MLD. 
 
 
 
 
 
Conclusion: Reduction in lung function, measured by 
spirometry, can be predicted by functional as well as physical 
lung dose, but no statistically significant difference in their 
predictive ability was observed in these patients. The actual 
biological impact of radiation on normal lung tissue might be 
underestimated in spirometry data (as well in 
patient/oncologist reported outcomes) since a significant 
fraction of the patients actually observe an improved lung 
function during treatment. This improvement is likely related 
to re-ventilation of obstructed airways due to tumour 
regression, which could mask underlying radiation damage. 
Another possibility is that regional ventilation may vary over 
a course of treatment. Analysis of 4D cone beam CT scans 
during treatment, and of post-treatment radiographic 
changes in follow-up CT scans may help untangle these 
“competing” effects. 
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Purpose or Objective: The study tested whether 
preoperative 5x5 Gy and consolidation chemotherapy is more 
locally efficacious than standard preoperative 
chemoradiation in “unresectable” rectal cancer. 
 
Material and Methods: Patients with fixed cT3 or cT4 cancer 
without distant metastases were randomized either to 5x5 Gy 
and 3 cycles of FOLFOX4 after one week rest (experimental 
group) or to 50.4 Gy delivered in 28 fractions given 
simultaneously with two 5-day cycles of 5-Fu 325 mg/m2/day 
and leucovorin 20 mg/m2/day in bolus during the first and 
fifth week of irradiation; 5 one-day infusions of oxaliplatin 50 
mg/m2 were given once a week at 1, 8, 15, 22, and 29 days 
of irradiation. 3 cycles of FOLFOX were chosen to keep 
overall neoadjuvant treatment time similar in the two 
groups. Postoperative chemotherapy in both groups was 
optional. For the second study part, because of the new 
publications, oxaliplatin was delivered to the two groups at 
the discretion of the participating centre. Both randomized 
groups underwent surgery about 12 weeks after starting 
irradiation and about 6-7 weeks after completing 
neoadjuvant treatment.  
 
Results: 541 patients were randomised and 515 were eligible 
for analysis; 261 in the experimental group and 254 in the 
control group of whom pelvic MR at baseline was respectively 
performed in 66% and 65% of patients. Oxaliplatin was given 
preoperatively to 70% of patients in the experimental group 
and to 66% in the control group, p=0.40. The incidence and 
severity of the neoadjuvant treatment acute toxicity was 
lower in the experimental group than in the control group, 
p=0.005; the overall toxicity rate being respectively 75% vs. 
83%, grade III-IV 23% vs. 21% and toxic deaths 1% vs. 3%. The 
postoperative complications rate was 29% of patients in the 
experimental group and 25% in the control group, p=0.18. R0 
resection rates (primary endpoint) and pathological complete 
response rates were respectively in the experimental group 
and in the control group 77% vs. 71% (p=0.081) and 16% vs. 
12% (p=0.17). Median follow-up was 35 months. At 3 years, 
rates of overall survival and disease-free survival were 
respectively in the experimental group and in the control 73% 
vs. 64.5% p=0.055 and 54% vs. 52%, p=0.69. At 3 years, 
cumulative incidence of local failure and cumulative 
incidence of distant metastases were respectively 22% vs. 
21%, p=0.82 and 30% vs. 27%, p=0.26. The incidence and 
